Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LOXL2 | Q9Y4K0 | 2/20 | 0.44 |
| ▸ | CDK2 | P24941 | 6/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | NOS3 | P29474 | 1/20 | 0.39 |
| ▸ | NOS1 | P29475 | 1/20 | 0.39 |
| ▸ | NOS2 | P35228 | 1/20 | 0.39 |
| ▸ | MMP13 | P45452 | 1/20 | 0.39 |
| ▸ | EGFR | P00533 | 1/20 | 0.38 |
| ▸ | ERN1 | O75460 | 1/20 | 0.38 |
| ▸ | LCK | P06239 | 1/20 | 0.37 |
| ▸ | MELK | Q14680 | 1/20 | 0.37 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.37 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.37 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19270622 | 0.86 | NOS3 (0.41) | CDK2HDAC1NOS3NOS1NOS2 | |
| SCHEMBL2903370 | 0.82 | ALDH1A1 (0.43) | LCK | |
| SCHEMBL2908877 | 0.78 | GAA (0.50) | LCK | |
| SCHEMBL2935296 | 0.77 | GABRP (0.48) | LCK | |
| SCHEMBL2901596 | 0.76 | ACHE (0.38) | HDAC1LCK | |
| SCHEMBL2909497 | 0.76 | GAA (0.43) | LCK | |
| SCHEMBL20606425 | 0.75 | SMN1; SMN2 (0.52) | CDK2 | |
| SCHEMBL2908530 | 0.75 | PLA2G2A (0.50) | LCKPLA2G2A | |
| SCHEMBL2908784 | 0.75 | PLA2G2A (0.51) | LCKPLA2G2A | |
| SCHEMBL17769119 | 0.75 | L3MBTL1 (0.57) | MMP13LCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170240652-A1 | ANTIBODIES AGAINST SEROTONIN, TRYPTOPHAN AND KYNURENINE METABOLITES AND USES THEREOF | NESTEC S.A. (CH) | 2017-08-24 | — | — | US | disclosed |
| US-20170240652-A1 | ANTIBODIES AGAINST SEROTONIN, TRYPTOPHAN AND KYNURENINE METABOLITES AND USES THEREOF | NESTEC S.A. (CH) | 2017-08-24 | — | — | US | disclosed |
| WO-2016079708-A1 | ANTIBODIES AGAINST SEROTONIN, TRYPTOPHAN AND KYNURENINE METABOLITES AND USES THEREOF | NESTEC S.A. (CH) | 2016-05-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170240652-A1 | ANTIBODIES AGAINST SEROTONIN, TRYPTOPHAN AND KYNURENINE METABOLITES AND USES THEREOF | TPH1, HTR5A, KYNU | LOXL2 3262/4885CDK2 4599/4885HDAC1 2781/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.